Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (101-110 of 181) with videos related to

Pageof 19
Sort By:
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Plos One|August 21, 2020
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective studySilvana Di Yacovo, Maria Saumoy, José Luís Sánchez-Quesada, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSFJuan Tiraboschi, Sofia Scévola, Sujan Dilly Penchala, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
Antiviral Therapy|May 12, 2004
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapineMontserrat Plana, Elena Ferrer, Catalina Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.
Pageof 19

Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppressionMaria S Di Yacovo, José Moltó, Elena Ferrer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 29, 2012
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot studyAnthony Mills, Donna Mildvan, Daniel Podzamczer, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
Plos One|August 21, 2020
Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective studySilvana Di Yacovo, Maria Saumoy, José Luís Sánchez-Quesada, et al.
AIDS (London, England)|March 28, 2003
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loadJuan A Arnaiz, Josep Mallolas, Daniel Podzamczer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 22, 2021
Total and Unbound Doravirine Concentrations and Viral Suppression in CSFJuan Tiraboschi, Sofia Scévola, Sujan Dilly Penchala, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
Antiviral Therapy|May 12, 2004
Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapineMontserrat Plana, Elena Ferrer, Catalina Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 2, 2015
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)Jose M Miro, Christian Manzardo, Elena Ferrer, et al.
Pageof 19